Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

A Spanish study found that nirsevimab prophylaxis significantly reduced infant hospitalizations, ICU admissions, and severe ...

Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings.

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Overall, 72% of 36,949 infants were immunized in the 2023-2024 RSV season with either the bivalent RSV prefusion F protein ...

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

Most infants hospitalised for RSV-related infections need oxygen support and critical care despite nirsevimab use, with similar severity across cases, a Spanish study shows.

Nirsevimab administration through March 31, 2024, was identified among infants from eligible pregnancies. Infant RSV ...

A meta-analysis indicates that the monoclonal antibody nirsevimab offers significant real-world protection against severe ...

Maternal RSV vaccination and nirsevimab were associated with a reduction in RSV hospitalization rates in infants aged 0 to 7 months during the 2024-2025 RSV season.

Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence. HealthDay News — Nirsevimab is effective for reducing the burden ...

Compared with 2018-2020 pooled rates, 2024-2025 RSV-associated hospitalization rates were lower among infants aged 0 to 7 months. HealthDay News — Maternal respiratory syncytial virus (RSV ...